Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD3 (CD3E)
AMX-500 (also known as VIR-5500) is a protease-activated T-cell engager that binds PSMA on tumor cells and CD3 on T-cells. Its two binding domains are masked by XTEN polypeptides joined through a tumor protease-cleavable linker, so activation occurs in the tumor microenvironment. It is studied in hormone-refractory prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05997615 | Phase 1 | Hormone-refractory Prostate Cancer | Recruiting | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hormone-refractory Prostate Cancer